Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide combined with chemotherapy for pediatric alveolar rhabdomyosarcoma
ChiCTR1900024911Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in alveolar rhabdomyosarcoma (ARMS), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective response rate. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
arsenic trioxide
03
Conditions
alveolar rhabdomyosarcoma (ARMS)
Beyond the preview
Go deeper on ChiCTR1900024911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024911.